Naptumomab Estafenatox

Bladder Cancer

NeoTX Therapeutics Ltd.monoclonal_antibodyPhase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 73/ 100

Competitive context

121 Active assets in the Bladder Cancer cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II G1 Therapeutics, Inc.	Phase 3	BBB
TRASTUZUMAB NKGen Biotech, Inc.	Phase 2	BB
Carboplatin G1 Therapeutics, Inc.	Phase 3	BB
VINBLASTINE University of Southern California	Phase 3	BB
Pembrolizumab Essen Biotech	Phase 3	BB

View all 50 →

Same molecule, other indications

Naptumomab Estafenatox is also rated in:

renal cell carcinomaDormant

B

Indicative ·

57 / 100

non-small cell lung carcinomaDormant

CCC

Indicative ·

55 / 100

estrogen-receptor positive breast cancerDormant

CC

Indicative ·

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.